8-K: Theriva Biologics Announces Positive Safety Data from VIRAGE Phase 2b Trial of VCN-01 in Pancreatic Cancer

Theriva Biologics reports positive safety outcomes from the second IDMC review of its VIRAGE Phase 2b clinical trial, indicating VCN-01 is well-tolerated in combination with chemotherapy for metastatic pancreatic cancer.

Summary

• Theriva Biologics announced positive outcomes from the second Independent Data Monitoring Committee (IDMC) review of the VIRAGE Phase 2b clinical trial.
• The trial is evaluating VCN-01 in combination with standard-of-care chemotherapy for newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).
• The IDMC found that VCN-01 was well-tolerated, and the adverse event (AE) profile was as expected for the patient population and medications studied.
• The VCN-01 AE profile was consistent with prior clinical trials, with common AEs being transient and reversible.
• These AEs were observed to be less frequent and of reduced CTCAE grade after the second VCN-01 dose (administered on day 92) compared to the first VCN-01 dose (administered on day 1).
• Patient enrollment in the VIRAGE trial was completed in September 2024, and topline clinical outcomes data are anticipated in Q2 2025.
• The trial enrolled 101 patients across 5 sites in the U.S. and 9 sites in Spain.

Sentiment

Score: 7

Explanation: The document presents positive safety data from a clinical trial, suggesting potential progress in treating pancreatic cancer. However, it's still early-stage data, and the ultimate success depends on future clinical outcomes and regulatory approvals.

Positives

• VCN-01 was found to be well-tolerated in combination with standard-of-care chemotherapy.
• The adverse event profile was consistent with prior clinical trials.
• The most common adverse events were transient and reversible.
• Adverse events were less frequent and of reduced severity after the second VCN-01 dose.
• The IDMC review supports the feasibility of repeated VCN-01 dosing in metastatic PDAC patients.

Risks

• The release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results could differ materially from current expectations due to various factors, including the company's ability to generate positive clinical data and obtain regulatory approval.

Future Outlook

Theriva Biologics anticipates releasing topline clinical outcomes data from the VIRAGE trial in Q2 2025, which, combined with previous feedback from the FDA and EMA, will guide the design of a potential Phase 3 registrational trial for discussion with regulatory agencies later this year.

Management Comments

• Steven A. Shallcross, CEO of Theriva Biologics, stated that the second positive IDMC review affirms the feasibility of repeated VCN-01 dosing in metastatic PDAC patients.
• Shallcross also mentioned that the company is working towards the release of topline clinical outcomes data in Q2 2025.

Industry Context

The announcement highlights the ongoing efforts to develop novel therapies for pancreatic cancer, a disease with high unmet need. The use of oncolytic viruses like VCN-01 in combination with standard chemotherapy represents a promising approach to improve treatment outcomes.

Comparison to Industry Standards

• The VIRAGE trial's design, using gemcitabine/nab-paclitaxel as standard-of-care, aligns with common treatment protocols for metastatic PDAC.
• Other companies, such as Celgene (now Bristol Myers Squibb) with Abraxane (nab-paclitaxel), have established the chemotherapy backbone used in this trial.
• The use of an oncolytic virus like VCN-01 is similar in concept to Amgen's Imlygic (talimogene laherparepvec) for melanoma, but targets a different cancer type and uses a different viral vector.
• The trial's endpoints, including overall survival and progression-free survival, are standard measures used in oncology clinical trials.

Stakeholder Impact

• Positive safety data could be encouraging for patients with pancreatic cancer and their families.
• Successful development of VCN-01 could benefit shareholders through increased company value.
• Positive trial outcomes could lead to potential partnerships and collaborations.

Next Steps

• The company plans to release topline clinical outcomes data from the VIRAGE trial in Q2 2025.
• Theriva Biologics intends to use the data, along with previous feedback from the FDA and EMA, to guide the design of a potential Phase 3 registrational trial for discussion with regulatory agencies later this year.

Key Dates

Keywords

VCN-01, VIRAGE, Pancreatic Cancer, Metastatic PDAC, Theriva Biologics, Clinical Trial, IDMC, Oncolytic Virus, Chemotherapy, Safety Data